Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
A phase 1/2 trial of Dose Level 1, VNX-101 in acute lymphoblastic leukaemia, diffuse large B-cell lymphoma, chronic lymphocytic leukaemia, non-Hodgkin lymphoma, follicular lymphoma and mantle cell lymphoma, run by Vironexis Biotherapeutics Inc., now recruiting.
Overview
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) is a phase 1/2 interventional study registered as NCT06533579 by Vironexis Biotherapeutics Inc., with 32 participants planned, started 2025-05-30 and due to reach its primary completion in 2027-06. Interventions recorded: Dose Level 1, VNX-101, Dose Level 2, VNX-101, Dose Level 3, VNX-101 and Dose Level 4, VNX-101.
Similar pages
not linked directly; found by shared links- TrialA Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies
Shares Non-Hodgkin lymphoma (all types), Chronic lymphocytic leukaemia, Diffuse large B-cell lymphoma and the tag pipeline.
- TrialDose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma
Shares Follicular lymphoma, Non-Hodgkin lymphoma (all types), Diffuse large B-cell lymphoma and the tag pipeline.
- TreatmentCTX112
Shares Mantle cell lymphoma, Follicular lymphoma, Chronic lymphocytic leukaemia, Diffuse large B-cell lymphoma and the tag pipeline.
- TrialStudy of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom
Shares Mantle cell lymphoma, Non-Hodgkin lymphoma (all types), Chronic lymphocytic leukaemia, Diffuse large B-cell lymphoma and the tag pipeline.
- TrialA Study of CTD402 in T-ALL/LBL Patients
Shares Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia and the tag pipeline.
- TrialPhase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma
Shares Follicular lymphoma, Diffuse large B-cell lymphoma and the tag pipeline.
- TrialStudy of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
Shares Non-Hodgkin lymphoma (all types), Diffuse large B-cell lymphoma and the tag pipeline.
- TreatmentCRC01
Shares Follicular lymphoma, Acute lymphoblastic leukaemia, Diffuse large B-cell lymphoma and the tag pipeline.